

REMARKS

Applicants elect the invention of Group VI (claims 20-21) for further prosecution in this application, without traverse. In light of this election, applicants cancel claims 1-19 directed to non-elected subject matter. The cancellation of these claims is without prejudice to Applicants' ability to file and obtain patent protection for claims directed to this cancelled subject matter in applications claiming priority to the present application under 35 U.S.C. § 120.


Claims 20-21 are amended to incorporate the subject matter of originally filed claim 13, upon which claims 20 and 21 previously depended.

Applicants add new claims 22 and 23 to incorporate the subject matter of originally filed claims 14 and 15, upon which claims 20 and 21 previously depended.

Applicants believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725.

None of these amendments adds new matter.

Respectfully submitted,



Andrea L. C. Robidoux
Registration No. 47,902
Agent for Applicant(s)
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Tel.: (617)444-6731
Fax.: (617)444-6438